In summary, the present work supports further optimization of the small-molecule Stat5 inhibitor IST5 for oral bioavailability for clinical development for therapies for solid tumors, hematological malignancies and myeloproliferative disorders. This evidence concerns the gene STAT5B and hematologic disorder.